Quick Answer
Coya Therapeutics, Inc. reported Stockholders Equity of $43.03 million for the year ending 2025.
- Coya Therapeutics, Inc. showed an increase of +8.7% in Stockholders Equity from 2024 to 2025.
- This data is from Coya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $1.96 million | Q2 2022: -$1.41 million | Q3 2022: -$5.36 million | Q1 2023: $16.15 million | Q2 2023: $13.25 million | Q3 2023: $10.09 million | Q1 2024: $32.39 million | Q2 2024: $35.26 million | Q3 2024: $32.01 million | Q1 2025: $33.37 million | Q2 2025: $28.31 million | Q3 2025: $27.28 million.
- Over the full 6 years of available data (2020 to 2025), Coya Therapeutics, Inc.'s Stockholders Equity has grown by 418.3%.
- Historical annual values: Fiscal year 2025: $43.03 million | Fiscal year 2024: $39.58 million | Fiscal year 2023: $35.64 million | Fiscal year 2022: -$8.39 million | Fiscal year 2021: $3.64 million | Fiscal year 2020: $8.30 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: